For healthcare professionals outside the U.S.
Print Text Size
 

This measurement is used for:

  • THALASSEMIA
  • MYELODYSPLASTIC SYNDROMES
  • SICKLE CELL DISEASE

Transcranial Doppler Ultrasonography

Identifying Patients at Risk for Stroke

Regular transfusion therapy can prevent stroke in children with sickle cell disease (SCD). Thus, identifying patients most likely to experience a stroke is an important aspect of care. The increased risk of stroke in children with SCD is due primarily to the progressive occlusion of large intracranial arteries.1

What is Transcranial Doppler Ultrasonography?

Transcranial Doppler (TCD) ultrasonography is a non-invasive diagnostic tool that allows for indirect real-time evaluation of intracranial cerebral circulation.1,2 It is used to measure abnormal blood flow velocity in large intracranial arteries, which can help to predict stroke risk in children (Table).3-5

Table. Stroke risk and blood flow velocity in children with SCD4,5

TAMMV, cm/s Stroke risk
< 170 Normal
170-199 Borderline
≥ 200 Abnormal

TAMMV = time-averaged mean of the maximum velocity.

Advantages of TCD Ultrasonography

TCD ultrasonography is safe, inexpensive, and reliable compared with other techniques. It can be repeated multiple times and can be used for continuous monitoring if needed.

How TCD Ultrasonography Works

TCD ultrasonography uses an ultrasonic beam (2 MHz frequency) produced from piezo-electric crystals that have been stimulated electrically.1,2 The ultrasonic beam bounces off erythrocytes within an artery. The reflected signal is received by a transducer and converted to an electric signal. This information is subtracted from the transmitted signal and processed to obtain a waveform (Figure).

TC Ultrasonography Recording from the Middle Cerebral Artery

Figure. Typical TCD ultrasonography recording from the middle cerebral artery (MCA).6

The velocity scale is shown on the left.

Reproduced from McCarville MB, et al. AJR. 2004;183:1117-22 © American Roentgen Ray Society.


The waveform allows accurate determination of blood flow velocities, flow direction, and addition of calculated parameters, such as pulsatility index (PI). PI is a reliable marker of resistance distal to the site being evaluated. The calculated blood flow velocities can be used to predict stroke risk.3

Predictive Value of TCD Ultrasonography

The predictive value of TCD ultrasonography correlates well with findings from magnetic resonance angiography (MRA), which is often used to study blood flow in children with SCD.

Imaging TCD ultrasonography adds further information, allowing visualization of arteries and angle-corrected blood velocity measurement.7

Guidelines for Screening with TCD Ultrasonography

Regular screening with TCD ultrasonography is recommended in the USA and UK for patients aged > 2 years.8-10

For further information about TCD:


Learn more about TCD ultrasonography >

References

  1. Kassab MY, et al. J Am Board Fam Med. 2007;20:65-71.
  2. Aaslid R, et al. J Neurosurg. 1982;57:769-74.
  3. Adams R, et al. N Engl J Med. 1992;326:605-10.
  4. Abboud MR, et al. Blood. 2004;103:2822-6.
  5. Adams RJ, et al. Ann Neurol. 1997;42:699-704.
  6. McCarville MB, et al. AJR Am J Roentgenol. 2004;183:1117-22.
  7. Krejza J, et al. AJR Am J Roentgenol. 2000;174:1297-303.
  8. Sickle Cell Society. 2008. Available from: www.sicklecellsociety.org. Accessed April 2011.
  9. National Institutes of Health (NIH). The Management of Sickle Cell Disease. 4th ed. Bethesda, MD; 2002. NIH publication 02-2117. Available from: www.nhlbi.nih.gov/health/prof/blood/sickle/sc_mngt.pdf. Accessed February 2011.
  10. National Health Service (NHS). 2009. Available from: https://www.evidence.nhs.uk/search?q=transcranial%20doppler%20and%20sickle%20cell. Accessed April 2011.

Send to a Colleague

Your privacy is important. We will not retain any of the information you enter on this page. Learn more about our privacy policy.

All fields are required.

Your name:
Your colleague's name:
Your colleague's e-mail address:

Leaving IronHealthalliance.com


You are now leaving the IronHealthalliance.com website by opening an external website independently operated and not managed by Novartis. Novartis assumes no responsibility for the site you are about to visit. If you do not wish to leave this site, click "Cancel." Otherwise, click "Continue".